Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Accounting Officer | February 26, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,884 |
Ending reported balance
After 2021-03-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-26 · Tax withholding · Disposed 2,218 · Balance 12,666 Row 2 · 2021-03-01 · Sale · Disposed 1,026 · Balance 11,640 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77). F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2021-03-01 · Sale · Disposed 610 · Balance 11,030 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95). Row 4 · 2021-03-01 · Sale · Disposed 915 · Balance 10,115 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85). Row 5 · 2021-03-01 · Sale · Disposed 231 · Balance 9,884 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27). |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 169 |
Reported balance
Holding disclosure · report date 2021-02-26 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 169 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77).
F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95).
F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85).
F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2013 Filed Oct 16, 2013 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 214 | $70.41 | $15,067.74 |
DisclosureSEC source: 0001209191-13-048483 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,129 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $70.41 (range $70.00 to $70.85). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 14, 2013 Filed Oct 16, 2013 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $51.75 | $58,218.75 |
DisclosureSEC source: 0001209191-13-048483 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2013 Filed Oct 16, 2013 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 468 | $33.82 | $15,827.76 |
DisclosureSEC source: 0001209191-13-048483 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2013 Filed Aug 6, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 938 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001209191-13-039411 · doc4.xml · derivative · entry 11 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 938 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2011. Read SEC document |
| August 05, 2013 Filed Aug 6, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 938 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0001209191-13-039411 · doc4.xml · derivative · entry 10 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 938 shares Expires 2020-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/04/2010. Read SEC document |
| August 05, 2013 Filed Aug 6, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $79.56 | $7,956.00 |
DisclosureSEC source: 0001209191-13-039411 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 05, 2013 Filed Aug 6, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,776 | $78.59 | $139,575.84 |
DisclosureSEC source: 0001209191-13-039411 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,850 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $78.59 (range $78.23 to $79.08). Read SEC document |
| August 05, 2013 Filed Aug 6, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 938 | $38.80 | $36,394.40 |
DisclosureSEC source: 0001209191-13-039411 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2013 Filed Aug 6, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 938 | $39.05 | $36,628.90 |
DisclosureSEC source: 0001209191-13-039411 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2013 Filed Aug 6, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-13-039411 · doc4.xml · derivative · entry 9 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 1,125 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2012. Read SEC document |
| August 02, 2013 Filed Aug 6, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $80.33 | $16,066.00 |
DisclosureSEC source: 0001209191-13-039411 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $80.33 (range $79.97 to $80.68). Read SEC document |
| August 02, 2013 Filed Aug 6, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 925 | $79.13 | $73,195.25 |
DisclosureSEC source: 0001209191-13-039411 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,950 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $79.13 (range $78.59 to $79.41). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2013 Filed Aug 6, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $37.86 | $42,592.50 |
DisclosureSEC source: 0001209191-13-039411 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 13,750 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-13-038696 · doc4.xml · derivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2023-07-29 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/30/2013. Read SEC document |
| July 25, 2013 Filed Jul 29, 2013 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 1,125 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-13-038172 · doc4.xml · derivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 1,125 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/25/2012. Read SEC document |
| July 25, 2013 Filed Jul 29, 2013 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 483 | $87.29 | $42,161.07 |
DisclosureSEC source: 0001209191-13-038172 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $87.29 (range $87.16 to $87.38). Read SEC document |
| July 25, 2013 Filed Jul 29, 2013 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 542 | $86.17 | $46,704.14 |
DisclosureSEC source: 0001209191-13-038172 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,233 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $86.17 (range $85.74 to $86.61). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 25, 2013 Filed Jul 29, 2013 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $84.38 | $8,438.00 |
DisclosureSEC source: 0001209191-13-038172 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,775 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 25, 2013 Filed Jul 29, 2013 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $48.74 | $54,832.50 |
DisclosureSEC source: 0001209191-13-038172 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2013 Filed Jul 17, 2013 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 469 | $0.00 Strike: $33.28 | $0.00 |
DisclosureSEC source: 0001209191-13-037017 · doc4.xml · derivative · entry 10 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 469 shares Expires 2019-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/16/2009. Read SEC document |
| July 16, 2013 Filed Jul 17, 2013 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 469 | $85.75 | $40,216.75 |
DisclosureSEC source: 0001209191-13-037017 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $85.75 (range $85.22 to $86.20). Read SEC document |
| July 16, 2013 Filed Jul 17, 2013 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 469 | $33.28 | $15,608.32 |
DisclosureSEC source: 0001209191-13-037017 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 1,125 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-13-037017 · doc4.xml · derivative · entry 9 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 1,125 shares Expires 2021-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/13/2011. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 469 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001209191-13-037017 · doc4.xml · derivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 469 shares Expires 2020-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/14/2010. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $87.33 | $8,733.00 |
DisclosureSEC source: 0001209191-13-037017 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,494 | $86.34 | $128,991.96 |
DisclosureSEC source: 0001209191-13-037017 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,850 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $86.34 (range $85.99 to $86.89). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $51.75 | $58,218.75 |
DisclosureSEC source: 0001209191-13-037017 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 469 | $33.82 | $15,861.58 |
DisclosureSEC source: 0001209191-13-037017 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2013 Filed May 17, 2013 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $80.50 | $8,050.00 |
DisclosureSEC source: 0001209191-13-027213 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · kind: Transaction made pursuant to Mr. Silva'a company approved trading plan under Rule 10b5-1. Read SEC document |
| May 15, 2013 Filed May 17, 2013 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 509 | $79.49 | $40,460.41 |
DisclosureSEC source: 0001209191-13-027213 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,850 F1 · kind: Transaction made pursuant to Mr. Silva'a company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $79.49 (range $79.19 to $79.77). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 06, 2013 Filed May 8, 2013 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 937 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0001209191-13-024876 · doc4.xml · derivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,813 Underlying: Common Stock · 937 shares Expires 2020-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments beginning on 02/04/2010. Read SEC document |
| May 06, 2013 Filed May 8, 2013 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommom Stock | 707 | $77.56 | $54,834.92 |
DisclosureSEC source: 0001209191-13-024876 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $77.56 (range $77.48 to $77.63). Read SEC document |
| May 06, 2013 Filed May 8, 2013 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 230 | $76.12 | $17,507.60 |
DisclosureSEC source: 0001209191-13-024876 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,457 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $76.12 (range $75.73 to $76.27). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 06, 2013 Filed May 8, 2013 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 937 | $39.05 | $36,589.85 |
DisclosureSEC source: 0001209191-13-024876 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2013 Filed May 6, 2013 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 937 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001209191-13-024162 · doc4.xml · derivative · entry 10 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,563 Underlying: Common Stock · 937 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments beginning on 02/03/2011. Read SEC document |
| May 03, 2013 Filed May 6, 2013 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $78.12 | $7,812.00 |
DisclosureSEC source: 0001209191-13-024162 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 03, 2013 Filed May 6, 2013 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $76.66 | $15,332.00 |
DisclosureSEC source: 0001209191-13-024162 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,850 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $76.66 (range $76.47 to $76.85). Read SEC document |
| May 03, 2013 Filed May 6, 2013 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 637 | $75.76 | $48,259.12 |
DisclosureSEC source: 0001209191-13-024162 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,050 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $75.76 (range $75.42 to $76.21). Read SEC document |
| May 03, 2013 Filed May 6, 2013 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 937 | $38.80 | $36,355.60 |
DisclosureSEC source: 0001209191-13-024162 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2013 Filed May 6, 2013 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-13-024162 · doc4.xml · derivative · entry 9 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,375 Underlying: Common Stock · 1,125 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments beginning on 02/02/2012. Read SEC document |
| May 02, 2013 Filed May 6, 2013 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 425 | $77.59 | $32,975.75 |
DisclosureSEC source: 0001209191-13-024162 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $77.59 (range $77.49 to $77.72). Read SEC document |
| May 02, 2013 Filed May 6, 2013 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $77.17 | $54,019.00 |
DisclosureSEC source: 0001209191-13-024162 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,175 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $77.17 (range $76.48 to $77.41). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 02, 2013 Filed May 6, 2013 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $37.86 | $42,592.50 |
DisclosureSEC source: 0001209191-13-024162 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2013 Filed Apr 29, 2013 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-13-022908 · doc4.xml · derivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,625 Underlying: Common Stock · 1,125 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 7/25/2012. Read SEC document |
| April 25, 2013 Filed Apr 29, 2013 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 725 | $80.79 | $58,572.75 |
DisclosureSEC source: 0001209191-13-022908 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $80.79 (range $80.52 to $81.13). Read SEC document |
| April 25, 2013 Filed Apr 29, 2013 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $80.24 | $32,096.00 |
DisclosureSEC source: 0001209191-13-022908 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,475 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $80.24 (range $79.52 to $80.50). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 25, 2013 Filed Apr 29, 2013 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $48.74 | $54,832.50 |
DisclosureSEC source: 0001209191-13-022908 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · derivative · entry 20 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 2,250 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/25/2012. Read SEC document |
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,375 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · derivative · entry 19 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 3,375 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| April 19, 2013 Filed Apr 23, 2013 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-13-022281 · doc4.xml · derivative · entry 18 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,125 Underlying: Common Stock · 4,500 shares Expires 2021-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/13/2011. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.